Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Good
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Good
|
New words:
Amgen, anemia, ataxia, blood, BMS, CEO, Chairman, circulating, Civik, conference, ctDNA, deep, Economy, expectedly, Foundation, Genentech, infrequent, inhibitory, Jerel, lesion, member, MYTHIC, NaN, Nov, oAntitumor, oEarly, oFinal, oIn, oMr, oOn, oRecommended, poly, polymerase, Prime, radiological, RECIST, red, regimen, rescind, serial, shrinkage, stable, subset, telangiectasia, Threonine, tYrosine, underwritten, unwritten, upsized, weekly
Removed:
Cowen, Goldman, LLC, Morgan, Piper, recurrent, Sandler, Stanley, stay, talazoparib
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view